TRINETRA › Sectors › Healthcare
Laurus Labs Limited (LAURUSLABS) — share price, P/E and fundamentals
Laurus Labs Limited (NSE: LAURUSLABS) closed at ₹2,405.50 on 30 Oct 2026, +167.3% over one year, against a 52-week range of ₹901.40 – ₹2,405.50.
In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹2,206 cr and net profit of ₹441 cr, a 20.0% net margin; revenue grew 33.4% and profit grew 119.4% year on year.
On four consecutive filed quarters its trailing P/E is 97.0; since 25 Apr 2025 its own P/E has ranged from 59.5 to 169.7 (median 96.2), and today's reading is higher than 51% of those 374 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 29.1%, ROCE 33.7%, debt-to-equity 0.41, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 73% of 63 sector peers; PBT margin higher than 78% of 63 sector peers; ROE higher than 94% of 63 sector peers.
Key figures
| Last close | ₹2,405.50 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +18.7% / +116.0% / +167.3% |
| 52-week low – high | ₹901.40 – ₹2,405.50 |
| Market capitalisation | ₹1,29,969 cr |
| Trailing P/E | 97.0 |
| Price / book | 21.45 |
| EV / EBITDA | 54.7 |
| Earnings yield | 1.0% |
| TTM EPS | ₹24.80 |
| TTM net profit | ₹1,340 cr |
| Quarter revenue | ₹2,206 cr |
| Quarter net profit | ₹441 cr |
| Net margin | 20.0% |
| Revenue growth (YoY) | +33.4% |
| Profit growth (YoY) | +119.4% |
| Return on equity | 29.1% |
| ROCE | 33.7% |
| Debt / equity | 0.41 |
| Current ratio | 1.31 |
| Free cash flow | ₹-59 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹294.3 cr |
Against Healthcare peers
| Metric | LAURUSLABS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 20.01 | 12.67 | 73 |
| PBT margin | 26.82 | 17.57 | 78 |
| ROE | 29.14 | 13.86 | 94 |
| ROCE | 33.65 | 16.59 | 91 |
| Debt / equity | 0.41 | 0.11 | 80 |
| FCF margin | -1.40 | 2.08 | 43 |
| Cash conversion | 1.01 | 1.25 | 34 |
| Trailing P/E | 97.00 | 43.07 | 92 |
Questions
What is the P/E ratio of Laurus Labs Limited?
Laurus Labs Limited's trailing P/E is 97.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 25 Apr 2025 its P/E has ranged 59.5–169.7.
What were Laurus Labs Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Laurus Labs Limited reported revenue of ₹2,206 cr and net profit of ₹441 cr (consolidated), filed with the exchange on 29 Oct 2026.
What is Laurus Labs Limited's ROE?
Return on equity is 29.1% based on the balance sheet dated 30 Sept 2026.
Does Laurus Labs Limited have debt?
Debt-to-equity is 0.41 on the balance sheet dated 30 Sept 2026.
What is LAURUSLABS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, LAURUSLABS traded between ₹901.40 and ₹2,405.50.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.